LabCorp announced today that its Covance Drug Development business has entered into a strategic technology agreement with GlaxoSmithKline (GSK). Under the terms of the agreement, GSK will use Covance’s Xcellerate Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model.   “We are thrilled to have the opportunity to collaborate with GSK,” said Dimitris Agrafiotis, chief data officer and head of technology products at Covance. “Xce...